NAFDAC Recalls 2 Batches Of Cardura XL Over Impurity Concerns

The National Agency for Food and Drugs Administration and Control (NAFDAC) has recalled two specific batches of hypertension drug, Cardura XL (Doxazosin), manufactured by the American pharmaceutical company, Viatris Inc. over impurity issues.

The affected lots, identified by the batch numbers 81470418163765 and 81470408163764, are being recalled due to failure of critical tests for impurity levels and degradation, potentially affecting patient safety.

Cardura XL contains doxazosin mesylate and is commonly used to treat high blood pressure and help men with enlarged prostate to urinate better.

The use of poor-quality drugs, such as those that do not meet impurity and degradation standards, poses significant health risks including allergic reactions, anxiety, harm to the patient, or in extreme cases, death.

NAFDAC urged anyone in possession of the affected Cardura XL lots to immediately halt the use or sale of the drug, instructing them to return the products to the nearest NAFDAC office.

Consumers who have used the drug and experienced any adverse effects are strongly encouraged to seek medical attention.